BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort

Anticancer Res. 2008 Jan-Feb;28(1A):305-8.

Abstract

Background: The genes RAS and BRAF have been shown to be frequently mutated in human thyroid carcinomas. The aim of this study was to genotype a cohort of 55 sporadic papillary thyroid carcinomas (PTC) and 44 sporadic medullary thyroid carcinomas (MTC) for the K-RAS codon 12 and BRAF codon 600 mutations.

Materials and methods: K-RAS and BRAF mutations were characterized by an enhanced polymerase chain reaction followed by restriction fragment length polymorphism analysis (PCR-RFLP).

Results: The K-RAS codon 12 mutation was found in 54.5% of the PTC and 40.9% of the MTC cases tested. The BRAF V600E mutation was detected in 27.3% of the PTC and 68.2% of the MTC samples. No significant association between K-RAS and BRAF mutations and clinicopathological parameters was found.

Conclusion: These data indicate that K-RAS and BRAF mutations were a frequent genetic event in our samples of sporadic PTC and MTC.

MeSH terms

  • Adult
  • Carcinoma, Medullary / genetics*
  • Carcinoma, Medullary / pathology
  • Carcinoma, Papillary / genetics*
  • Carcinoma, Papillary / pathology
  • Female
  • Genes, ras*
  • Greece
  • Humans
  • Male
  • Middle Aged
  • Mutation*
  • Paraffin Embedding
  • Polymerase Chain Reaction
  • Polymorphism, Restriction Fragment Length
  • Proto-Oncogene Proteins B-raf / genetics*
  • Thyroid Neoplasms / genetics*
  • Thyroid Neoplasms / pathology

Substances

  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf